Indication
CAR
3 clinical trials
4 products
Clinical trial
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility ProtocolStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Anti-CD19 CAR T-cellsClinical trial
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Phase IProduct
Phase II